Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-06-04, Stock:JNJ, The news for the past five days is as follows:
2018-05-25: NEWS1: U.S. jury fails to reach verdict in latest J&J talc trial.NEWS2: U.S. jury fails to reach verdict in latest J&J talc trial over asbestos claims.NEWS3: No Verdict Reached in J&J Baby Powder Case.NEWS4: J&J Jury Fails to Reach Verdict in S.C. Cancer Suit Tied to Talc.NEWS5: A Focus on Eye Care Is Setting Up Johnson & Johnson Stock for the Future.NEWS6: A Focus on Eye Care Is Setting Up Johnson & Johnson Stock for the Future.NEWS7: 10 Top Health-Care Stocks That Never Break a Sweat.NEWS8: 10 Top Health-Care Stocks That Never Break a Sweat.NEWS9: 7 Dow Titans Rolling Over.NEWS10: 7 Dow Titans Rolling Over.NEWS11: A Focus on Eye Care Is Setting Up Johnson & Johnson Stock for the Future.NEWS12: AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint.NEWS13: AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint.NEWS14: Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval.NEWS15: Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval.NEWS16: One Click for the 500 Best High Yield Investments.NEWS17: One Click for the 500 Best High Yield Investments.NEWS18: 7 Dow Titans Rolling Over.NEWS19: Dow 30 Stock Roundup: GE&apos;s Transportation Unit to Merge With Wabtec, J&J & Glaxo&apos;s HIV Drug Gets EU Approval.NEWS20: 3 Likely Reasons Geron Stock Is Sizzling Hot Right Now.NEWS21: 3 Likely Reasons Geron Stock Is Sizzling Hot Right Now.NEWS22: AbbVie&apos;s Imbruvica&apos;s Phase III Study Meets Primary Endpoint.NEWS23: What Is Geron Corporation's Downside Risk?.NEWS24: What Is Geron Corporation's Downside Risk?.NEWS25: 3 Likely Reasons Geron Stock Is Sizzling Hot Right Now.NEWS26: What Is Geron Corporation&apos;s Downside Risk?.NEWS27: J&J Jury Asks Judge to Slap Cancer Warning on Baby Powder.NEWS28: 5 Top Stock Trades for Friday Morning.NEWS29: 5 Top Stock Trades for Friday Morning.
2018-05-29: NEWS1: Tuesday's Market Sell-Off: The 52 Week Highs and Lows.NEWS2: Johnson & Johnson Becomes Oversold.NEWS3: Johnson & Johnson Becomes Oversold.NEWS4: Johnson & Johnson (JNJ) Shares Cross 3% Yield Mark.NEWS5: Johnson & Johnson (JNJ) Shares Cross 3% Yield Mark.NEWS6: Notable Tuesday Option Activity: PCYG, CELG, JNJ.NEWS7: Notable Tuesday Option Activity: PCYG, CELG, JNJ.NEWS8: These 3 Stocks Shot Up 50% in 2017 -- Are They Still Buys?.NEWS9: These 3 Stocks Shot Up 50% in 2017 -- Are They Still Buys?.NEWS10: These 3 Stocks Shot Up 50% in 2017 -- Are They Still Buys?.NEWS11: Johnson & Johnson to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference.NEWS12: 5 Clinical-Stage Biotech Stocks to Buy Under $10.NEWS13: Incyte’s Revenue Trend in Q1 2018.NEWS14: Stocks to Watch: Apple, Qualcomm, Disney, 21st Century Fox, Chevron, Johnson & Johnson, Starbucks.NEWS15: [$$] Juries Weigh Cases Over Alleged Harms of Johnson & Johnson Baby Powder.
2018-05-30: NEWS1: How Has JNJ’s Medical Devices Business Evolved in Recent Years?.NEWS2: How to Find a Growth Stock.NEWS3: How to Find a Growth Stock.NEWS4: 7 Inflation-Beating Stocks to Consider for This New Reality.NEWS5: JNJ’s Medical Devices Growth Plans amid Changing Market Dynamics.NEWS6: Johnson & Johnson: Focus on Entrepreneurial Organizational Model.NEWS7: Johnson & Johnson’s Strategy to Broaden Scope of Innovation Model.NEWS8: Perrigo Company (PRGO) Ex-Dividend Date Scheduled for May 31, 2018.NEWS9: Perrigo Company (PRGO) Ex-Dividend Date Scheduled for May 31, 2018.NEWS10: How Is Merck’s Hospital Acute Care Segment Positioned?.NEWS11: Johnson & Johnson in the Changing Consumer Market Landscape.NEWS12: Add Bucks County to list of those suing opioid manufacturers, distributors.NEWS13: Today’s Research Reports on Stocks to Watch: Axovant Sciences and Johnson & Johnson.NEWS14: Johnson & Johnson Hit 52-Week Low after Stopping Darzalex Trial.NEWS15: See what the IHS Markit Score report has to say about Johnson & Johnson..
2018-05-31: NEWS1: How Novartis’s Business Segments Did in Q1.NEWS2: Assessing GlaxoSmithKline’s Quarterly Revenues.NEWS3: Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis.NEWS4: Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis.NEWS5: Top Diabetes Stocks to Buy Today.NEWS6: How Is JNJ Maintaining Its Momentum in Interventional Solutions?.NEWS7: Johnson & Johnson and the Baby Powder Litigations.NEWS8: How JNJ Is Recreating Its Commercial Model for Medical Devices.NEWS9: Amgen Focused on Advancing Oncology Research Programs in 2018.NEWS10: Johnson & Johnson Responds to Meet Consumer Needs Faster.NEWS11: Sage’s Brexanolone IV: FDA Grants Priority Review.NEWS12: Discussing the Shift in Johnson & Johnson’s Research Strategy.NEWS13: Johnson & Johnson’s Growth Strategy: Expand Emerging Channels.NEWS14: 7 Inflation-Beating Stocks to Consider for This New Reality.NEWS15: 7 Inflation-Beating Stocks to Consider for This New Reality.
2018-06-01: NEWS1: Imerys unit settles talc claims for at least $5 million: Bloomberg.NEWS2: ITOT, JPM, XOM, JNJ: Large Inflows Detected at ETF.NEWS3: ITOT, JPM, XOM, JNJ: Large Inflows Detected at ETF.NEWS4: How JNJ Is Positioned to Achieve Growth in the Orthopedics Space.NEWS5: Johnson & Johnson’s Over-the-Counter Growth through Innovation.NEWS6: Imerys Unit Said to Settle Talc Claims for at Least $5 Million.NEWS7: Discussing JNJ’s Strategy for Advancing Stroke Treatments.NEWS8: How Johnson & Johnson Is Driving Growth for Beauty Products.NEWS9: Johnson & Johnson Is Reinventing Its Oral Care Franchise.NEWS10: Breakfast Technical Briefing on Johnson & Johnson and Three Other Additional Healthcare Stocks.NEWS11: [$$] Big Pharma on mission to bring immunotherapy to more patients.NEWS12: Celgene Appoints J&J's David Elkins As EVP, CFO, Succeeding Peter Kellogg.NEWS13: Celgene Appoints J&J's David Elkins As EVP, CFO, Succeeding Peter Kellogg.

Answer: Rise